Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19.
Glucagon-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are two classes of treatments for type 2 diabetes, which enhance the well-known 'incretin effect' of increased insulin secretion in response to food intake. This concise review introduces both types of incretin-based therapies and focuses on the extra-pancreatic effect of GLP-1 on body weight. As well as improving glycaemic control in subjects with type 2 diabetes, these treatments have the additional benefits of improving weight management in these patients, with GLP-1 receptor agonists causing weight loss and DPP-4 inhibitors being weight neutral.
胰高血糖素样肽 1（GLP-1）类似物和二肽基肽酶-4（DPP-4）抑制剂是两种治疗 2 型糖尿病的药物，它们增强了因进食而增加的胰岛素分泌的著名“肠促胰岛素效应”。这篇简明的综述介绍了这两种基于肠促胰岛素的治疗方法，并重点介绍了 GLP-1 对体重的胰外作用。除了改善 2 型糖尿病患者的血糖控制外，这些治疗方法还有额外的益处，可改善这些患者的体重管理，GLP-1 受体激动剂可导致体重减轻，而 DPP-4 抑制剂则对体重无影响。
